QQQ   427.30 (+0.34%)
AAPL   167.90 (-0.06%)
MSFT   411.47 (-0.09%)
META   509.88 (+3.18%)
GOOGL   156.28 (+0.52%)
AMZN   182.30 (+0.56%)
TSLA   150.75 (-3.02%)
NVDA   855.50 (+1.80%)
AMD   155.93 (+1.24%)
NIO   4.03 (+3.07%)
BABA   69.40 (+0.84%)
T   16.14 (+0.12%)
F   12.12 (+0.66%)
MU   114.79 (-1.32%)
GE   156.69 (+0.66%)
CGC   7.80 (+20.18%)
DIS   113.91 (+0.86%)
AMC   2.90 (-2.68%)
PFE   25.34 (-0.31%)
PYPL   62.72 (-0.85%)
XOM   118.99 (+0.30%)
QQQ   427.30 (+0.34%)
AAPL   167.90 (-0.06%)
MSFT   411.47 (-0.09%)
META   509.88 (+3.18%)
GOOGL   156.28 (+0.52%)
AMZN   182.30 (+0.56%)
TSLA   150.75 (-3.02%)
NVDA   855.50 (+1.80%)
AMD   155.93 (+1.24%)
NIO   4.03 (+3.07%)
BABA   69.40 (+0.84%)
T   16.14 (+0.12%)
F   12.12 (+0.66%)
MU   114.79 (-1.32%)
GE   156.69 (+0.66%)
CGC   7.80 (+20.18%)
DIS   113.91 (+0.86%)
AMC   2.90 (-2.68%)
PFE   25.34 (-0.31%)
PYPL   62.72 (-0.85%)
XOM   118.99 (+0.30%)
QQQ   427.30 (+0.34%)
AAPL   167.90 (-0.06%)
MSFT   411.47 (-0.09%)
META   509.88 (+3.18%)
GOOGL   156.28 (+0.52%)
AMZN   182.30 (+0.56%)
TSLA   150.75 (-3.02%)
NVDA   855.50 (+1.80%)
AMD   155.93 (+1.24%)
NIO   4.03 (+3.07%)
BABA   69.40 (+0.84%)
T   16.14 (+0.12%)
F   12.12 (+0.66%)
MU   114.79 (-1.32%)
GE   156.69 (+0.66%)
CGC   7.80 (+20.18%)
DIS   113.91 (+0.86%)
AMC   2.90 (-2.68%)
PFE   25.34 (-0.31%)
PYPL   62.72 (-0.85%)
XOM   118.99 (+0.30%)
QQQ   427.30 (+0.34%)
AAPL   167.90 (-0.06%)
MSFT   411.47 (-0.09%)
META   509.88 (+3.18%)
GOOGL   156.28 (+0.52%)
AMZN   182.30 (+0.56%)
TSLA   150.75 (-3.02%)
NVDA   855.50 (+1.80%)
AMD   155.93 (+1.24%)
NIO   4.03 (+3.07%)
BABA   69.40 (+0.84%)
T   16.14 (+0.12%)
F   12.12 (+0.66%)
MU   114.79 (-1.32%)
GE   156.69 (+0.66%)
CGC   7.80 (+20.18%)
DIS   113.91 (+0.86%)
AMC   2.90 (-2.68%)
PFE   25.34 (-0.31%)
PYPL   62.72 (-0.85%)
XOM   118.99 (+0.30%)
Free Trial

Compare Stocks

→ A.I. Pioneer Issues Urgent Warning to Americans (From TradeSmith) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$1.21
-6.2%		$0.00
$0.84
▼
$1.61
$228.12M1.31948,007 shs275,247 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover
The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
0.00%0.00%0.00%0.00%-23.78%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
1.8992 of 5 stars		3.50.00.00.01.15.00.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
3.00
Buy$6.50441.67% Upside

Current Analyst Ratings

Latest LCTX, IMU, and FARN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
2/13/2024
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy ➝ Buy$7.00
2/5/2024
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingOverweight ➝ Overweight$6.00
(Data available from 4/18/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
$8.94M25.31N/AN/A$0.35 per share3.43

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
-$21.49M-$0.13N/AN/AN/A-240.20%-31.95%-19.89%5/9/2024 (Estimated)

Latest LCTX, IMU, and FARN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/7/2024Q4 2023
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
-$0.07-$0.03+$0.04-$0.03$4.74 million$2.09 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
N/A
2.14
2.14

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
62.47%

Insider Ownership

CompanyInsider Ownership
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
28.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Lineage Cell Therapeutics, Inc. stock logo
LCTX
Lineage Cell Therapeutics
68188.53 million135.56 millionNot Optionable

IMU, LCTX, and MDG1 Headlines

SourceHeadline
Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate DevelopmentLineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development
finance.yahoo.com - April 1 at 8:33 AM
5 Simple Wealth-Building Tips For This Generations Forward-Thinkers5 Simple Wealth-Building Tips For This Generation's Forward-Thinkers
msn.com - March 28 at 9:03 PM
Optimistic Buy Rating for Lineage Cell Therapeutics Ahead of OpRegen Study Data ReleaseOptimistic Buy Rating for Lineage Cell Therapeutics Ahead of OpRegen Study Data Release
markets.businessinsider.com - March 19 at 8:06 AM
Puma Biotechnology dips after dismissal of its suit was granted by a federal judgePuma Biotechnology dips after dismissal of its suit was granted by a federal judge
seekingalpha.com - March 18 at 4:07 PM
15 Best Anti-Aging Foods for Youthful Skin15 Best Anti-Aging Foods for Youthful Skin
finance.yahoo.com - March 18 at 12:44 PM
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor SymposiumLineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
finance.yahoo.com - March 18 at 8:11 AM
Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor SymposiumLineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium
businesswire.com - March 18 at 8:00 AM
Billionaire Ken Fisher and Corporate Insiders Are Buying These 10 StocksBillionaire Ken Fisher and Corporate Insiders Are Buying These 10 Stocks
finance.yahoo.com - March 14 at 6:19 PM
RG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation SummitRG6501 (OpRegen®) Phase 1/2a Clinical Study 24 Month Results to Be Featured at 2024 Retinal Cell & Gene Therapy Innovation Summit
finance.yahoo.com - March 13 at 8:17 AM
RG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology MeetingRG6501 (OpRegen®) Preclinical Engraftment Results to Be Presented at 2024 Association for Research in Vision and Ophthalmology Meeting
finance.yahoo.com - March 11 at 9:02 AM
Buy Rating Affirmed for Lineage Cell Therapeutics Amidst Promising Regenerative Therapy AdvancementsBuy Rating Affirmed for Lineage Cell Therapeutics Amidst Promising Regenerative Therapy Advancements
markets.businessinsider.com - March 11 at 6:59 AM
Optimistic Buy Rating for Lineage Cell Therapeutics Amid Pipeline Progress and Strategic PartnershipsOptimistic Buy Rating for Lineage Cell Therapeutics Amid Pipeline Progress and Strategic Partnerships
markets.businessinsider.com - March 8 at 5:10 PM
Buy Rating Affirmed for Lineage Cell Therapeutics Amid Strong Financials and Promising OpRegen Therapy ResultsBuy Rating Affirmed for Lineage Cell Therapeutics Amid Strong Financials and Promising OpRegen Therapy Results
markets.businessinsider.com - March 8 at 5:10 PM
Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call TranscriptLineage Cell Therapeutics, Inc. (AMEX:LCTX) Q4 2023 Earnings Call Transcript
insidermonkey.com - March 8 at 5:01 PM
LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023LCTX Stock Earnings: Lineage Cell Therapeutics Beats EPS, Beats Revenue for Q4 2023
msn.com - March 7 at 10:58 PM
Lineage Cell Therapeutics Inc. Reports Q4 and Full Year 2023 Financial ResultsLineage Cell Therapeutics Inc. Reports Q4 and Full Year 2023 Financial Results
finance.yahoo.com - March 7 at 10:58 PM
Lineage Cell Therapeutics: Q4 Earnings InsightsLineage Cell Therapeutics: Q4 Earnings Insights
benzinga.com - March 7 at 5:58 PM
Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateLineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
businesswire.com - March 7 at 4:01 PM
A Preview Of Lineage Cell Therapeuticss EarningsA Preview Of Lineage Cell Therapeutics's Earnings
benzinga.com - March 6 at 4:55 PM
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 7, 2024
finance.yahoo.com - February 29 at 10:08 AM
Lineage Cell Therapeutics Stock (AMEX:LCTX), Analyst Ratings, Price Targets, PredictionsLineage Cell Therapeutics Stock (AMEX:LCTX), Analyst Ratings, Price Targets, Predictions
benzinga.com - February 14 at 1:49 AM
Strong Buy Rating for Lineage Therap Backed by Promising Developments in Spinal Cord Injury TherapyStrong Buy Rating for Lineage Therap Backed by Promising Developments in Spinal Cord Injury Therapy
markets.businessinsider.com - February 13 at 4:34 PM
Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct OfferingLineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
finance.yahoo.com - February 9 at 9:41 AM
Lineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct OfferingLineage Cell Therapeutics Announces Closing of $14.0 Million Registered Direct Offering
businesswire.com - February 9 at 9:15 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Lineage Cell Therapeutics logo

Lineage Cell Therapeutics

NYSEAMERICAN:LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers ANP1, an allogeneic auditory neuron progenitor cell transplant, which is in preclinical development for the treatment of debilitating hearing loss; and PNC1, an allogeneic photoreceptor cell transplant, which is in preclinical development for the treatment of vision loss due to photoreceptor dysfunction or damage. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Immunomic Therapeutics, Inc., for the treatment of glioblastoma multiforme. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.